Interactions between a novel cell surface glycoprotein and the H‐2K and H‐2D antigens on myeloma tumor cells

Esteban Celis, Heman N. Eisen

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Previous studies have shown that when a subline of plasmacytoma LPC‐1 is grown in ascites form, the tumor cells harvested after 10–12 days (“late” cells) are resistant to lysis by cytotoxic T lymphocytes (CTL), apparently because the cell surface H‐2‐encoded molecules are blocked by a trypsin‐sensitive glycoprotein of approximately 160 kdaltons. The glycoprotein (gp 160) is produced, and accumulates on the cell surface, as the growing cells enter the stationary phase. In contrast, LPC‐1 cells harvested from the peritoneal cavity early in the transplantation cycle (ca. 4 days), while in exponential growth (“early” cells), have far less gp 160 and are susceptible to lysis by CTL. It is shown that, compared with early cells, the late LPC‐1 cells are far less effective in adsorbing antibodies to products of the H‐2 Kd and H‐2 Dd alleles, but only slightly less effective in adsorbing antibodies to la antigen, and fully effective in adsorbing antibodies to several antigens not related to H‐2 (e.g. PC.1, gp70, gp100, B220). The differences suggest that gp160 might preferentially block H‐2‐encoded molecules (especially K and D) Gp160 was also detected on another myeloma, MOPC 315 OPEC, a subline of MOPC 315, where it also appeared to block H‐2 molecules but not PC.1. Additional evidence for an interaction between gp160 and H‐2 molecules was obtained when sonicated membrane fragments were used to elicit secondary CTL responses to H‐2 in culture. The response could be elicited by fragments from early but not from late LPC‐1 cells, unless the late cells were treated with subtilisin (to remove gp 160) before sonication.

Original languageEnglish (US)
Pages (from-to)455-461
Number of pages7
JournalEuropean Journal of Immunology
Volume10
Issue number6
DOIs
StatePublished - Jan 1 1980

Fingerprint

Membrane Glycoproteins
Antigens
Neoplasms
Cytotoxic T-Lymphocytes
Antibodies
Glycoproteins
Subtilisin
Sonication
Plasmacytoma
Peritoneal Cavity
Ascites
Transplantation
Alleles

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Interactions between a novel cell surface glycoprotein and the H‐2K and H‐2D antigens on myeloma tumor cells. / Celis, Esteban; Eisen, Heman N.

In: European Journal of Immunology, Vol. 10, No. 6, 01.01.1980, p. 455-461.

Research output: Contribution to journalArticle

@article{6492c044f97c4c17ac6ed8b71d565b2a,
title = "Interactions between a novel cell surface glycoprotein and the H‐2K and H‐2D antigens on myeloma tumor cells",
abstract = "Previous studies have shown that when a subline of plasmacytoma LPC‐1 is grown in ascites form, the tumor cells harvested after 10–12 days (“late” cells) are resistant to lysis by cytotoxic T lymphocytes (CTL), apparently because the cell surface H‐2‐encoded molecules are blocked by a trypsin‐sensitive glycoprotein of approximately 160 kdaltons. The glycoprotein (gp 160) is produced, and accumulates on the cell surface, as the growing cells enter the stationary phase. In contrast, LPC‐1 cells harvested from the peritoneal cavity early in the transplantation cycle (ca. 4 days), while in exponential growth (“early” cells), have far less gp 160 and are susceptible to lysis by CTL. It is shown that, compared with early cells, the late LPC‐1 cells are far less effective in adsorbing antibodies to products of the H‐2 Kd and H‐2 Dd alleles, but only slightly less effective in adsorbing antibodies to la antigen, and fully effective in adsorbing antibodies to several antigens not related to H‐2 (e.g. PC.1, gp70, gp100, B220). The differences suggest that gp160 might preferentially block H‐2‐encoded molecules (especially K and D) Gp160 was also detected on another myeloma, MOPC 315 OPEC, a subline of MOPC 315, where it also appeared to block H‐2 molecules but not PC.1. Additional evidence for an interaction between gp160 and H‐2 molecules was obtained when sonicated membrane fragments were used to elicit secondary CTL responses to H‐2 in culture. The response could be elicited by fragments from early but not from late LPC‐1 cells, unless the late cells were treated with subtilisin (to remove gp 160) before sonication.",
author = "Esteban Celis and Eisen, {Heman N.}",
year = "1980",
month = "1",
day = "1",
doi = "10.1002/eji.1830100610",
language = "English (US)",
volume = "10",
pages = "455--461",
journal = "European Journal of Immunology",
issn = "0014-2980",
publisher = "Wiley-VCH Verlag",
number = "6",

}

TY - JOUR

T1 - Interactions between a novel cell surface glycoprotein and the H‐2K and H‐2D antigens on myeloma tumor cells

AU - Celis, Esteban

AU - Eisen, Heman N.

PY - 1980/1/1

Y1 - 1980/1/1

N2 - Previous studies have shown that when a subline of plasmacytoma LPC‐1 is grown in ascites form, the tumor cells harvested after 10–12 days (“late” cells) are resistant to lysis by cytotoxic T lymphocytes (CTL), apparently because the cell surface H‐2‐encoded molecules are blocked by a trypsin‐sensitive glycoprotein of approximately 160 kdaltons. The glycoprotein (gp 160) is produced, and accumulates on the cell surface, as the growing cells enter the stationary phase. In contrast, LPC‐1 cells harvested from the peritoneal cavity early in the transplantation cycle (ca. 4 days), while in exponential growth (“early” cells), have far less gp 160 and are susceptible to lysis by CTL. It is shown that, compared with early cells, the late LPC‐1 cells are far less effective in adsorbing antibodies to products of the H‐2 Kd and H‐2 Dd alleles, but only slightly less effective in adsorbing antibodies to la antigen, and fully effective in adsorbing antibodies to several antigens not related to H‐2 (e.g. PC.1, gp70, gp100, B220). The differences suggest that gp160 might preferentially block H‐2‐encoded molecules (especially K and D) Gp160 was also detected on another myeloma, MOPC 315 OPEC, a subline of MOPC 315, where it also appeared to block H‐2 molecules but not PC.1. Additional evidence for an interaction between gp160 and H‐2 molecules was obtained when sonicated membrane fragments were used to elicit secondary CTL responses to H‐2 in culture. The response could be elicited by fragments from early but not from late LPC‐1 cells, unless the late cells were treated with subtilisin (to remove gp 160) before sonication.

AB - Previous studies have shown that when a subline of plasmacytoma LPC‐1 is grown in ascites form, the tumor cells harvested after 10–12 days (“late” cells) are resistant to lysis by cytotoxic T lymphocytes (CTL), apparently because the cell surface H‐2‐encoded molecules are blocked by a trypsin‐sensitive glycoprotein of approximately 160 kdaltons. The glycoprotein (gp 160) is produced, and accumulates on the cell surface, as the growing cells enter the stationary phase. In contrast, LPC‐1 cells harvested from the peritoneal cavity early in the transplantation cycle (ca. 4 days), while in exponential growth (“early” cells), have far less gp 160 and are susceptible to lysis by CTL. It is shown that, compared with early cells, the late LPC‐1 cells are far less effective in adsorbing antibodies to products of the H‐2 Kd and H‐2 Dd alleles, but only slightly less effective in adsorbing antibodies to la antigen, and fully effective in adsorbing antibodies to several antigens not related to H‐2 (e.g. PC.1, gp70, gp100, B220). The differences suggest that gp160 might preferentially block H‐2‐encoded molecules (especially K and D) Gp160 was also detected on another myeloma, MOPC 315 OPEC, a subline of MOPC 315, where it also appeared to block H‐2 molecules but not PC.1. Additional evidence for an interaction between gp160 and H‐2 molecules was obtained when sonicated membrane fragments were used to elicit secondary CTL responses to H‐2 in culture. The response could be elicited by fragments from early but not from late LPC‐1 cells, unless the late cells were treated with subtilisin (to remove gp 160) before sonication.

UR - http://www.scopus.com/inward/record.url?scp=0018942376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018942376&partnerID=8YFLogxK

U2 - 10.1002/eji.1830100610

DO - 10.1002/eji.1830100610

M3 - Article

AN - SCOPUS:0018942376

VL - 10

SP - 455

EP - 461

JO - European Journal of Immunology

JF - European Journal of Immunology

SN - 0014-2980

IS - 6

ER -